Prediction of Radial Distance of Extraprostatic Extension From Pretherapy Factors

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 2, 2007, Pages 411-418

  Schwartz, David J ^a   Sengupta, Shomik ^b   Hillman, David W ^a   Sargent, Daniel J ^a   Cheville, John C ^a   Wilson, Torrence M ^b   Mynderse, Lance A ^b   Choo, Richard ^a   Davis, Brian J ^a  

^a MAYO CLINIC   (United States)

^b DEPARTMENT OF UROLOGY   (United States)

Author keywords

Extraprostatic extension; Pathology; Prostate cancer; Prostatectomy; Radiotherapy

Indexed keywords

ANTIGENS; BIOPSY; PATHOLOGY; PATIENT MONITORING; RADIOTHERAPY; TUMORS;

EXTRAPROSTATIC EXTENSION; PROSTATE CANCER; PROSTATECTOMY;

ONCOLOGY;

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER STAGING; CANCER THERAPY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; SEMINAL VESICLE;

AGED; ANALYSIS OF VARIANCE; BIOPSY, NEEDLE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 34548495358     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.03.016     Document Type: Article

References (25)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Sengupta S., Myers R.P., Slezak J., et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol 174 (2005) 2191-2196
3. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7. Cancer 88 (2000) 2110-2115
4. Partin A.W., Kattan M.W., Subong E.N., et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer: A multi-institutional update. [Erratum appears in JAMA 1997;278:118]. JAMA 277 (1997) 1445-1451
5. Kattan M.W., Stapleton A.M., Wheeler T.M., et al. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma. Cancer 79 (1997) 528-537
6. Davis B.J., Pisansky T.M., Wilson T.M., et al. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer 85 (1999) 2630-2637
7. Sohayda C., Kupelian P.A., Levin H.S., et al. Extent of extracapsular extension in localized prostate cancer. Urology 55 (2000) 382-386
8. Teh B.S., Bastasch M.D., Wheeler T.M., et al. IMRT for prostate cancer: Defining target volume based on correlated pathologic volume of disease. Int J Radiat Oncol Biol Phys 56 (2003) 184-191
9. Gleason D.F., and Mellinger G.T. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111 (1974) 58-64
10. American Joint Committee on Cancer, Manual for staging of cancer (1997), Lippincott, Philadelphia
11. Klee G.G., Dodge L.A., Zincke H., et al. Measurement of serum prostate specific antigen using IMx prostate specific antigen assay. J Urol 151 (1994) 94-98
12. Oesterling J.E., Jacobsen S.J., Chute C.G., et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270 (1993) 860-864
13. Myers R.P. Practical surgical anatomy for radical prostatectomy. Urol Clin North Am 28 (2001) 473-490
14. Bostwick D.G., Myers R.P., and Oesterling J.E. Staging of prostate cancer. Semin Surg Oncol 10 (1994) 60-72
15. Schned A.R., Wheeler K.J., Hodorowski C.A., et al. Tissue-shrinkage correction factor in the calculation of prostate cancer volume. Am J Surg Pathol 20 (1996) 1501-1506
16. Davis B.J., Haddock M.G., Wilson T.M., et al. Treatment of extraprostatic cancer in clinically organ-confined prostate cancer by permanent interstitial brachytherapy: Is extraprostatic seed placement necessary?. Tech Urol 6 (2000) 70-77
17. Sakr W.A., Wheeler T.M., Blute M., et al. Staging and reporting of prostate cancer-Sampling of the radical prostatectomy specimen. Cancer 78 (1996) 366-368
18. Partin A.W., Mangold L.A., Lamm D.M., et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 58 (2001) 843-848
19. Greene F.L., Page D.L., Fleming I.D., et al. AJCC cancer staging manual. 6th ed. (2002), Springer, New York
20. Bostwick D.G., Qian J., Bergstralh E., et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 155 (1996) 1361-1367
21. Kleer E., and Oesterling J.E. PSA and staging of localized prostate cancer. Urol Clin North Am 20 (1993) 695-704
22. Kupelian P.A., Katcher J., Levin H.S., et al. Stage T1-2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 37 (1997) 1043-1052
23. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18 (2000) 1164-1172
24. Chao K.K., Goldstein N.S., Yan D., et al. Clinicopathologic analysis of extracapsular extension in prostate cancer: Should the clinical target volume be expanded posterolaterally to account for microscopic extension?. Int J Radiat Oncol Biol Phys 65 (2006) 999-1007
25. Michalski J.M., Winter K., Purdy J.A., et al. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose level V. Int J Radiat Oncol Biol Phys 62 (2005) 706-713